Close Menu

NEW YORK ─ Ahrensburg, Germany-based Abviris, the developer of a lateral flow test for cancer detection, said on Tuesday that it has raised almost €2 million ($2.4 million) in financing to expand its business.

Current investor High-Tech Gründerfonds, a venture capital investment firm based in Bonn, Germany, was the "the most significant" investor in the financing, a company representative said in an email, declining to name the other investors in the financing.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.